EU Biosimilar Filings, Opinions And Approvals
First Biosimilar Insulin Aspart Gets CHMP OK, Next Step Approval
Executive Summary
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event. Developments include the CHMP giving the green light to the EU’s first biosimilar version of the diabetes drug, insulin aspart, from Sanofi.